Data from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3

Read full text
Authors: Mariateresa Fulciniti, Yao Yao, Tommaso Perini, Jessica Fong Ng, Anaïs Schavgoulidze, Shuhui Deng, Jian Cui, Jessica Encinas, Francesco Ladisa, Ryan M. Young, Charles B. Epstein, Cassandra White
+11 more Christopher J. Ott, Annamaria Gullà, Shannon M. Matulis, Adam Samuel Sperling, Eugenio Morelli, Lawrence Boise, Moritz Binder, Raphael Elie Szalat, Mehmet Samur, Kenneth Carl Anderson, Nikhil C. Munshi
Cited by: 0

Abstract

Abstract Transcription factors and their cofactors are major and selective nononcogene dependencies in multiple myeloma cells. By performing a gain-of-function perturbation screen in human multiple myeloma cell lines, we identified the inhibitor of DNA binding (ID) genes as putative suppressors of multiple myeloma cell fitness. Among them, ID2 was found to be downregulated in multiple myeloma patient cells and acted as a tumor suppressor by directly binding and repressing the basic helix-loop-helix factor TCF3, also known as E2A. Lower ID2 expression in multiple myeloma cells conferred a proliferative advantage by increasing TCF3 activity, leading to a dependency on this transcription factor. In contrast, ID2 overexpression reduced TCF3 binding to DNA, which resulted in cell-cycle arrest and a halt in multiple myeloma cell proliferation. The myeloma bone marrow milieu supported this process by further decreasing the expression of ID2 and enhancing TCF3 activity, partly via IL6, revealing a mechanism by which the tumor microenvironment affects multiple myeloma cell behavior. Significance: Multiple myeloma cells exploit the oncogenic and proliferative potential of TCF3 by downregulating the transcriptional regulator ID2, a process facilitated by the bone marrow microenvironment.

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Wnt/β-catenin signaling in development and cancer Genomics and Chromatin Dynamics

Publication details

Publication date
12 January 2026